Spartin (SPART) (Internal Region) Antikörper

Produktnummer ABIN570717

Produktdetails

Target: Spartin (SPART)

Bindungsspezifität: Internal Region

Reaktivität: Human

Wirt: Ziege

Klonalität: Polyklonal

Konjugat: Unkonjugiert

Applikation: ELISA, Immunofluorescence (IF), Western Blotting (WB)

Verwendungszweck: SPARTIN

Sequenz: EASGTDVKQL DQGNK

Kreuzreaktivität: Human

Aufreinigung: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Güteklasse: Verified

Immunogen: Peptide with sequence C-EASGTDVKQLDQGNK, from the internal region of the protein sequence according to NP_055902.1.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

Western Blot: Approx 70 kDa band observed in lysates of cell line HeLa (calculated MW of 72.8 kDa according to NP_055902.1). Recommended concentration: 1-3 μg/mL.

Peptide ELISA: antibody detection limit dilution 1:8000.

Kommentare:

Immunofluorescence: HeLa show dimished signals after knock down of expresssion by introduction of siRNA.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Minimize freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.

Antigendetails

Target: Spartin (SPART)

Andere Bezeichnung: SPART

Hintergrund: SPG20, spastic paraplegia 20 (Troyer syndrome), KIAA0610, SPARTIN, TAHCCP1, OTTHUMP00000018254, spastic paraplegia 20, spastic paraplegia 20, spartin (Troyer syndrome), trans-activated by hepatitis C virus core protein 1

Gen-ID: 23111

NCBI Accession: NP_055902